文献速递胸部肿瘤

度伐利尤单抗联合放化疗治疗局限期小细胞肺癌

Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer.
PubMed 文献 · Eur J Cancer · 2022-04-29

这项单臂II期研究纳入51例局限期小细胞肺癌患者,接受4周期依托泊苷+顺铂+度伐利尤单抗,第3周期起同步胸部放疗52.5 Gy/25次,后续度伐利尤单抗巩固治疗最长2年,中位随访26.6个月,中位无进展生存期14.4个月,24个月总生存率67.8%,安全性可耐受。

要点

  • 中位随访26.6个月时,中位无进展生存期14.4个月(95%CI 10.3-未达到),24个月无进展生存率42.0%。
  • 中位总生存期未达到,24个月总生存率67.8%。
  • 可接受预防性脑照射的患者中,预防性脑照射组(n=22)以脑转移为首发失败事件的比例13.6%,低于未照射组(n=21)的42.9%(P=0.033)。

核心结论

  • 度伐利尤单抗联合同步放化疗治疗局限期小细胞肺癌显示出有前景的临床疗效,安全性可耐受,推动其进入随机研究验证。

研究设计与样本

  • 单臂II期研究,纳入51例局限期小细胞肺癌患者,50例纳入全分析集。
  • 治疗方案为4周期依托泊苷+顺铂+度伐利尤单抗每3周一次,第3周期化疗免疫治疗时开始胸部放疗52.5 Gy/25次每日一次,同步放化疗加度伐利尤单抗后予度伐利尤单抗巩固治疗每4周一次、最长至入组后2年,推荐预防性脑照射。
  • 试验注册号NCT03585998。

主要发现

  • 中位随访26.6个月,中位无进展生存期14.4个月(95%CI 10.3-未达到),24个月无进展生存率42.0%。
  • 中位总生存期未达到,24个月总生存率67.8%。
  • PD-L1阳性组(n=22)与PD-L1阴性组(n=20)相比,无进展生存期无显著延长(HR 0.70,95%CI 0.31-1.58),总生存期亦无显著延长(HR 0.64,95%CI 0.22-1.84)。
  • 在43例适合预防性脑照射的患者中,预防性脑照射组(n=22)以脑转移为首发失败事件的比例为13.6%,未照射组(n=21)为42.9%,差异有统计学意义(P=0.033)。
  • 出现若干3级或4级不良事件,经适当支持治疗均得到良好管理。

关键数值与推荐

  • 中位无进展生存期14.4个月(95%CI 10.3-未达到),24个月无进展生存率42.0%。
  • 24个月总生存率67.8%,中位总生存期未达到。
  • PD-L1阳性组(n=22)vs PD-L1阴性组(n=20):无进展生存期HR 0.70(95%CI 0.31-1.58),总生存期HR 0.64(95%CI 0.22-1.84),均无显著差异。
  • 预防性脑照射组(n=22)vs 未照射组(n=21):以脑转移为首发失败事件比例13.6% vs 42.9%(P=0.033)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The current standard treatment for limited-stage small-cell lung cancer (LS-SCLC) is chemotherapy with concurrent chemoradiotherapy (CCRT). METHODS: In this single-arm phase II study, patients with LS-SCLC received four cycles of etoposide, cisplatin, and durvalumab every 3 weeks. Thoracic radiotherapy of 52.5 Gy in 25 once-daily fractions was started with the third cycle of chemoimmunotherapy. After CCRT plus durvalumab, patients received durvalumab consolidation therapy every 4 weeks for a maximum of 2 years after study enrolment. Prophylactic cranial irradiation (PCI) was recommended. RESULTS: Fifty-one patients were enrolled, and 50 were included in the full analysis set. With the median follow-up duration of 26.6 months, the median PFS was 14.4 months (95% confidence interval: 10.3-NA), and the 24-month PFS rate was 42.0%. The median overall survival was not reached with a 24-month overall survival rate of 67.8%. The positive PD-L1 group (n = 22) was not associated with longer PFS (hazard ratio, 0.70; 0.31-1.58) and overall survival (0.64; 0.22-1.84) compared with the negative PD-L1 group (n = 20). Among the 43 patients who were candidates for PCI treatment, the PCI group (n = 22) had significantly fewer events of brain metastasis as the first failure sites compared to the no PCI group (n = 21) (13.6% vs. 42.9%, P = 0.033). There were several grade 3 or 4 adverse events which were well managed with appropriate supportive care. CONCLUSIONS: Durvalumab with CCRT for LS-SCLC exhibited promising clinical efficacy with a tolerable safety profile, prompting its validation in a randomized study. TRIAL REGISTRATION: NCT03585998.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Park S, Noh JM, Choi YL, et al. Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer. Eur J Cancer. 2022. PMID: 35500460. doi:10.1016/j.ejca.2022.03.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。